NANO MRNA Co., Ltd., The Current Fiscal Year Net Income Loss to Narrow

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Nov 14, 2024 3:00 pm JST Revision

4571 NANO MRNA Co., Ltd. 【J-GAAP】

Guidance Update Report

NANO MRNA Co., Ltd. <4571> [TSE-G] announced a performance revision in the afternoon session on November 14th (15:00). The consolidated net income/loss for the fiscal year ending March 2025 has been revised upward from an expected loss of 1.2 billion yen to a loss of 994 million yen (compared to a loss of 780 million yen in the previous period), indicating a reduction in the loss margin.

Furthermore, The company continued to decline to disclose its earnings forecast for April to September (first half).

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	ー	ー	ー	ー	－	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 New	101	-520	-474	-476	-6.7	0	Nov 14, 2024	J-GAAP
Revision Rate	－	－	－	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	51	-1,242	-1,192	-1,206	-17.1	0	May 14, 2024	J-GAAP
Mar, 2025 New	108	-893	-856	-994	-14.1	0	Nov 14, 2024	J-GAAP
Revision Rate	+111.8%	+28.1%	+28.2%	+17.6%	+17.6%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	44	-346	-278	-303	-4.3	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	101	-520	-474	-476	-6.7	0	Nov 14, 2024	J-GAAP
YoY	+129.5%	-50.3%	-70.5%	-57.1%	-56.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	202	-1,246	-1,104	-1,310	-18.7	0	May 12, 2023	J-GAAP
Mar, 2024	135	-864	-749	-780	-11.1	0	May 14, 2024	J-GAAP
Mar, 2025 Guidance	108	-893	-856	-994	-14.1	0	Nov 14, 2024	J-GAAP
YoY	-20.0%	-3.4%	-14.3%	-27.4%	-26.8%